Consolidated total income of the company stood at Rs 427.3 crore for the quarter under consideration. It was Rs 582.1 crore for the same pe...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

"Breckenridge Pharmaceutical Inc (BPI) has received final approval for its abbreviated new drug application (ANDA) for Everolimus tablets f...

"Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules fro...

Expats at the helm can help improve corporate governance and transparency

Natco's Lanthanum Carbonate strengths are generic equivalent of Shire Development LLC's Fosrenol chewable tablets and are indicated to redu...

Natco has launched pomalidomide capsules in strengths of 1 mg, 2 mg and 4 mg in India.

Natco Pharma has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets.

The company has received "final approval of abbreviated new drug application from the US Food and Drug Administration for generic version o...

Kothur facility predominantly caters to regulated international markets. EIR is given after the completion of the inspection by the USFDA.

"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.

The drug, used to prevent organ rejection after a kidney or liver transplant, generated sales of $43.5 mn for the 12-mth period ending July.

According to IMS health, Copaxone 40 mg/mL had US sales of nearly USD 411.5 million for the 12 months ending June 30, 2014, it added.

The decision by the US court covers several patents for the chemical composition of Copaxone, methods of using the product and processes fo...

On the number of applications received and rejected in 2011-12, Scindia said, 43,183 requests have been filed, of which 364 were rejected.

We have mostly targeted unaffordable life saving drugs which are either unavailable or in-adequately available at an exorbitant cost. These...

The drug regulator (DCGI) acted afer the US firm filed a written complaint citing serious side-effects that the generic may cause.